Biological approach of anticancer activity of new benzimidazole derivatives
- 1 February 2014
- journal article
- Published by Springer Science and Business Media LLC in Pharmacological Reports
- Vol. 66 (1), 100-106
- https://doi.org/10.1016/j.pharep.2014.01.001
Abstract
A series of new benzimidazole derivatives, earlier synthesized, was tested in vitro as new bioreductive prodrugs with the potential anticancer activity. Their effect on the DNA destruction and growth inhibition into selected tumor cell lines at normoxia and hypoxia conditions was determined. The human lung adenocarcinoma A549 cell line was used to determine the anticancer activity of the analyzed compounds by using WST-1 assay. The apoptosis test (caspase 3/7 assay) was used to define the cytotoxic way of tumor cells death. Additionally test In situ DNA Damage Assay Kit was applied to recognize the DNA destruction. Four of the examined compounds (1, 3, 7, 9) show a very good antiproliferative effect and three of them are specific for hypoxia conditions (2, 4, 8). Compound 8 is the most cytotoxic against human lung adenocarcinoma A549 cells at hypoxic conditions. Hypoxia/normoxia cytotoxic coefficient of compound 8 (4.75) is close to hypoxia/normoxia cytotoxic coefficient of tirapazamine (5.59) - reference substance in our experiments and this parameter locates it between mitomycin C and 2-nitroimidazole (misonidazole). The screening test of the caspase-dependent apoptosis proved that the exposure of compounds 1-2 and 7-8 against A549 cells for a 48 h promote apoptotic cell death. Additionally, the test of the DNA damage established that compounds 1, 2, 7, 8 are specific agents for the hypoxia-selective cytotoxicity of nitrobenzimidazoles [6,26].Keywords
This publication has 22 references indexed in Scilit:
- New benzimidazole derivatives with potential cytotoxic activity--study of their stability by RP-HPLC.Acta Biochimica Polonica, 2012
- Genz-644282, a Novel Non-Camptothecin Topoisomerase I Inhibitor for Cancer TreatmentClinical Cancer Research, 2011
- Biological activity of bis-benzimidazole derivatives on DNA topoisomerase I and HeLa, MCF7 and A431 cellsJournal of Enzyme Inhibition and Medicinal Chemistry, 2009
- Synthesis and biological activity evaluation of 1H-benzimidazoles via mammalian DNA topoisomerase I and cytostaticity assaysEuropean Journal of Medicinal Chemistry, 2009
- Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I StudyClinical Cancer Research, 2008
- Bioreductive Drugs: from Concept to ClinicClinical Oncology, 2007
- HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxiaCell Metabolism, 2006
- Some new bi- and ter-benzimidazole derivatives as topoisomerase I inhibitorsIl Farmaco, 2003
- Activation of Vascular Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1Molecular and Cellular Biology, 1996
- Zur Darstellung der BenzimidazoleEuropean Journal of Organic Chemistry, 1952